Genocea Biosciences (NASDAQ:GNCA) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCAGet Rating) in a research note issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Robert W. Baird reduced their target price on shares of Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th.

Shares of GNCA stock opened at $0.39 on Wednesday. Genocea Biosciences has a 12-month low of $0.30 and a 12-month high of $2.86. The firm has a market capitalization of $22.61 million, a price-to-earnings ratio of -0.63 and a beta of 1.45. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 0.15. The firm has a fifty day moving average of $0.98 and a 200-day moving average of $1.19.

Genocea Biosciences (NASDAQ:GNCAGet Rating) last announced its earnings results on Thursday, March 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.01). During the same period in the previous year, the business earned ($0.18) EPS. Research analysts expect that Genocea Biosciences will post -0.76 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in shares of Genocea Biosciences during the 4th quarter worth about $25,000. Renaissance Technologies LLC acquired a new position in shares of Genocea Biosciences during the 4th quarter worth about $32,000. Commonwealth Equity Services LLC boosted its stake in shares of Genocea Biosciences by 49.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 31,981 shares of the biotechnology company’s stock worth $37,000 after buying an additional 10,576 shares during the last quarter. Morgan Stanley boosted its stake in shares of Genocea Biosciences by 197.5% during the 2nd quarter. Morgan Stanley now owns 16,504 shares of the biotechnology company’s stock worth $39,000 after buying an additional 10,957 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Genocea Biosciences by 25.4% during the 4th quarter. Northern Trust Corp now owns 70,837 shares of the biotechnology company’s stock worth $82,000 after buying an additional 14,368 shares during the last quarter. Institutional investors own 59.25% of the company’s stock.

About Genocea Biosciences (Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.

Further Reading

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.